Skip to main content

Table 1 Clinicopathological characteristics of Yale cohorts

From: Quantitative assessment of invasive mena isoforms (Menacalc) as an independent prognostic marker in breast cancer

  Cohort 1 Cohort 2 Combined
Characteristic N (%) N (%) N (%)
All patients 501 296 797
Age (y)    
   <50 146 (29.1) 96 (32.4) 242 (30.4)
   ≥50 355 (70.8) 200 (67.6) 555 (69.6)
Nodal Status    
   positive 267 (53.2) 59 (19.9) 326 (40.9)
   negative 234 (46.7) 160 (54.1) 394 (49.4)
   unknown 0 (0) 77 (26.0) 77 (9.7)
Tumor Size (mm)    
   ≤2 155 (30.9) 148 (50.0) 303 (38.0)
   2 to 5 251 (50.1) 78 (26.4) 388 (48.7)
   ≥5 55 (11.0) 4 (1.3)  
   unknown 40 (8.0) 66 (22.3) 106 (13.3)
ER (IHC)    
   positive (1 to 3) 251 (50.1) 164 (55.4) 415 (52.1)
   negative (0) 234 (46.7) 97 (32.8) 331 (41.5)
   unknown 16 (3.2) 35 (11.8) 51 (6.4)
PR (IHC)    
   positive (1 to 3) 241 (48.1) 33 (11.1) 274 (34.4)
   negative (0) 233 (46.5) 221 (74.7) 454 (57.0)
   unknown 27 (5.4) 42 (14.2) 69 (8.6)
HER2 (IHC)    
   positive (2 to 3) 86 (17.2) 30 (10.1) 116 (14.6)
   negative (0 to 1) 393 (78.4) 213 (72.0) 606 (76.0)
   unknown 22 (4.4) 53 (17.9) 75 (9.4)
Follow-up (m)    
   median (range) 105.1 (2.39 to 498.03) 120.0 (3 to 385) 113.0 (2.4 to 250)
  1. IHC, immunohistochemistry; m, months; N, number; y, years